Erythrodermic psoriasis with regression after prophylaxis with isoniazid and antidepressant therapy: case report.

An 83 year old woman, exhibiting severe psoriasis, was treated conventionally (phototherapy, acitretin, and cyclosporine). After poor clinical results and significant changes in laboratory procedures, those treatments were suspended. She was then being prepared to be submitted to biological treatment, when preliminary results disclosed a 30 mm PPD. Complete improvement occurred [only] after introducing prophylactic therapy for tuberculosis and anti-depressive medication.

[1]  Petros P Sfikakis,et al.  The first decade of biologic TNF antagonists in clinical practice: lessons learned, unresolved issues and future directions. , 2010, Current directions in autoimmunity.

[2]  P. C. van de Kerkhof.  The relevance of biologics for the treatment of patients with psoriasis , 2009, The British journal of dermatology.

[3]  A. Gottlieb,et al.  Evaluation and management of psoriasis: an internist's guide. , 2009, The Medical clinics of North America.

[4]  J. Saurat,et al.  Tuberculosis screening in patients with psoriasis before antitumour necrosis factor therapy: comparison of an interferon‐γ release assay vs. tuberculin skin test , 2009, The British journal of dermatology.

[5]  K. Gordon,et al.  Long‐term efficacy of biologics in the treatment of psoriasis: what do we really know? , 2009, Dermatologic therapy.

[6]  A. Gottlieb,et al.  Current biologic treatments for psoriasis. , 2009, Dermatology nursing.

[7]  E. Berardesca,et al.  Biologic Therapies for Psoriasis , 2009, The Journal of Rheumatology.

[8]  L. Kircik,et al.  Anti-TNF agents for the treatment of psoriasis. , 2009, Journal of drugs in dermatology : JDD.

[9]  A. Menter,et al.  Tuberculosis and tumour necrosis factor‐α inhibitor therapy: a report of three cases in patients with psoriasis. Comprehensive screening and therapeutic guidelines for clinicians , 2009, The British journal of dermatology.

[10]  June K. Robinson,et al.  Tuberculosis in the age of biologic therapy. , 2008, Journal of the American Academy of Dermatology.

[11]  M. Lebwohl,et al.  National Psoriasis Foundation consensus statement on screening for latent tuberculosis infection in patients with psoriasis treated with systemic and biologic agents. , 2008, Journal of the American Academy of Dermatology.

[12]  M. Y. Güleç,et al.  Temperament and character profile of patients with psoriasis , 2008, Journal of the European Academy of Dermatology and Venereology : JEADV.

[13]  James T. Elder,et al.  Psoriasis: epidemiology. , 2007, Clinics in dermatology.

[14]  L. Puig-Sanz.  [Psoriasis, a systemic disease?]. , 2007, Actas dermo-sifiliograficas.

[15]  I. Hanta,et al.  Isoniazid intervention for latent tuberculosis among 86 patients with rheumatologic disease administered with anti-TNFα , 2007, Clinical Rheumatology.

[16]  G. Krueger,et al.  Psoriasis--recent advances in understanding its pathogenesis and treatment. , 2005, Journal of the American Academy of Dermatology.

[17]  K. Papp,et al.  Integrating Biologic Agents into Management of Moderate-to-Severe Psoriasis: A Consensus of the Canadian Psoriasis Expert Panel , 2004, Journal of cutaneous medicine and surgery.

[18]  Lúcia Arruda,et al.  Tratamento sistêmico da psoríase. Parte II: imunomoduladores biolÓgicos , 2004 .

[19]  V. Ho.  The use of ciclosporin in psoriasis: a clinical review , 2004, The British journal of dermatology.

[20]  R. Edlich,et al.  Modern concepts of the diagnosis and treatment of psoriasis. , 2009, Journal of environmental pathology, toxicology and oncology : official organ of the International Society for Environmental Toxicology and Cancer.

[21]  B. Kirby,et al.  TNF alpha inhibitors in the treatment of psoriasis and psoriatic arthritis. , 2005, BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy.

[22]  J. Weinberg,et al.  Advances in therapy for psoriasis: an overview of infliximab, etanercept, efalizumab, alefacept, adalimumab, tazarotene, and pimecrolimus. , 2005, Current pharmaceutical design.